CLS Q4: Softer sales than expected during the quarter - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

CLS Q4: Softer sales than expected during the quarter - Redeye

{newsItem.title}

Redeye provides an update following CLS’s Q4 2024 report. The results came in softer than we expected, and we argue that the company has an important year ahead, proving it can increase its sales and decrease costs. We make minor downward changes to our 2025e sales estimate and adjust our capital raising assumptions, rendering an updated fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1082683/cls-q4-softer-sales-than-expected-during-the-quarter?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt